patient is directed to rinse twice a day for 4 weeks. each rinse is 15 ml of Periactive

patient is directed to rinse twice a day for 4 weeks. each rinse is 10 ml of Periactive

Periodontal Diseases

PeriActive

Evaluation and Comparison of Efficacy of PeriActive Mouthwash to Chlorhexidine 0.12% Mouth Rinse

Phase IV Study to Evaluate and Compare the Efficacy of PeriActive Mouthwash to Chlorhexidine 0.12% Rinse With Regards to Managing Post-surgical Inflammation Associated With Dental Implant Surgery

trial results will be published for dentists to see

Izun Pharma Ltd

Jerusalem Perio Center

Herzog Hospital

OrasaltsTM
1 level scoop of OrasaltsTM will be dissolved in warm water. Participants will rinse and gargle the mouth for 30 seconds, then expel and not swallow the mixture, twice daily

Sea salt
1 level scoop of sea salt will be dissolved in warm water. Participants will rinse and gargle the mouth for 30 seconds, then expel and not swallow the mixture, twice daily

Gingivitis

OrasaltsTM mouthwash is composed of 119.5g of natural sea salt, Arnica montana 30C, Echinacea angustifolia 30C, Staphysagria 30C, Phosphorus 30C, Hepar sulphuris 30C, 0.27g cinnamon and 0.27g of liquorice

OrasaltsTM

Sea salt

University of Johannesburg

The Efficacy of OrasaltsTM in the Treatment of Gingivitis

MGI is a non-invasive method, used by the researcher, to assess inflammation of the gingiva in all 40 participants, at each consultation.

QGBI will be used by the participants to rate gingival bleeding on a daily basis.

Dr J. Pellow

Beginning as soon as symptoms arise during chemoradiotherapy, patients receive Vaccinium myrtillus extract/Macleaya cordata alkaloids/Echinacea angustifolia extract granules PO QID. Patients may continue to receive Vaccinium myrtillus extract/Macleaya cordata alkaloids/Echinacea angustifolia extract granules for up to 4 weeks after completion of radiation therapy for a maximum of 11 weeks.

Beginning as soon as symptoms arise during chemoradiotherapy, patients receive placebo PO QID. Patients may continue to receive placebo for up to 4 weeks after completion of radiation therapy for a maximum of 11 weeks.

Mucositis

Recurrent Squamous Cell Carcinoma of the Hypopharynx

Recurrent Squamous Cell Carcinoma of the Larynx

Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity

Recurrent Squamous Cell Carcinoma of the Nasopharynx

Recurrent Squamous Cell Carcinoma of the Oropharynx

Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity

Recurrent Verrucous Carcinoma of the Larynx

Recurrent Verrucous Carcinoma of the Oral Cavity

Stage III Squamous Cell Carcinoma of the Hypopharynx

Stage III Squamous Cell Carcinoma of the Larynx

Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity

Stage III Squamous Cell Carcinoma of the Nasopharynx

Stage III Squamous Cell Carcinoma of the Oropharynx

Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity

Stage III Verrucous Carcinoma of the Larynx

Stage III Verrucous Carcinoma of the Oral Cavity

Stage IV Squamous Cell Carcinoma of the Hypopharynx

Stage IV Squamous Cell Carcinoma of the Nasopharynx

Stage IVA Squamous Cell Carcinoma of the Larynx

Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity

Stage IVA Squamous Cell Carcinoma of the Oropharynx

Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity

Stage IVA Verrucous Carcinoma of the Larynx

Stage IVA Verrucous Carcinoma of the Oral Cavity

Stage IVB Squamous Cell Carcinoma of the Larynx

Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity

Stage IVB Squamous Cell Carcinoma of the Oropharynx

Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity

Stage IVB Verrucous Carcinoma of the Larynx

Stage IVB Verrucous Carcinoma of the Oral Cavity

Tongue Cancer

placebo

quality-of-life assessment

questionnaire administration

Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules

Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy

A Phase 2 Placebo Controlled Randomized Study of the Effect of SAMITAL on Severity and Duration of Mucositis Induced by Chemoradiation for Head and Neck Cancer (HNC)

The 2 treatment groups will be compared using the Mantel-Haenszel test, stratified by disease site and type of therapy, using a two-sided test at the alpha= 0.10 level of significance. Since emphasis is placed on the accurate estimation of treatment effect for use in the planning of a future confirmatory trial, corresponding estimates of effect size will also be computed along with 90% confidence intervals.

The 2 treatment groups will be compared. The Mantel-Haenszel test, stratified by disease site and type of therapy, will be used for these comparisons.

The 2 treatment groups will be compared. Will be analyzed using Mann-Whitney U tests. All secondary analyses will be carried out using two-sided tests at the 10% level of significance.

Roswell Park Cancer Institute

National Cancer Institute (NCI)

Patients received a 1-mg test dose of alemtuzumab, and the following day, alemtuzumab was administered at 10 mg/dose intravenously for 10 days

Alemtuzumab

Sex: Female, Male

Race/Ethnicity, Customized

Response to treatment at 3 months after the first dose of alemtuzumab. The parameters for hematologic improvement (HI) and complete response (CR) were defined according to the International Working Group (IWG) criteria. The IWG criteria for HI define specific responses of cytopenias in the 3 hematopoietic lineages: erythroid (HI-E), platelet (HI-P), and neutrophil (HI-N).7 The HIs are measured in patients with pretreatment abnormal values: hemoglobin level less than 110 g/L (11 g/dL) or RBC-transfusion dependence, platelet count less than 100 × 109/L or platelet-transfusion dependence, absolute neutrophil count (ANC) less than 1.0 × 109/L.
The parameters for CR include less than 5% marrow blasts without evidence of dysplasia and normalization of peripheral blood counts, including a hemoglobin level of 110 g/L (11 g/dL) or more (in patients not receiving erythropoietin or transfusions), a neutrophil count of 1.5 × 109/L or more, and a platelet count of 100 × 109/L.

Response to Treatment - Hematologic Improvement or Complete Response

Overall Study

Chris Hourigan MD

Myelodysplastic Syndromes

Alemtuzumab (Campath)

Alemtuzumab Is Safe and Associated With High Response Rates In Selected Patients With Myelodysplastic Syndrome

National Institutes of Health Clinical Center, 9000 Rockville Pike

A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome

A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome (MDS)

echinacea tennesseensis/upala

Evaluation and Comparison of Efficacy of PeriActive Mouthwash to Chlorhexidine 0.12% Mouth Rinse

The Efficacy of OrasaltsTM in the Treatment of Gingivitis

Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy

A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome

Najkompletnija baza ljekovitog bilja potpomognuta znanošću